Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
PDR001
-
PD-1 checkpoint inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03484923 (CPDR001J2201)
Previously treated unresectable or metastatic melanoma
Phase 2
195
Objective Response Rate (ORR)
Spartalizumab (PDR001) 400mg i.v. Q4W + LAG525 (to be tested in unselected
patients and LAG-3 positive patients)
Spartalizumab 400mg i.v. Q4W + capmatinib
Spartalizumab 400mg i.v. Q4W + canakinumab
Spartalizumab 400mg i.v. Q4W + ribociclib
Adult patients with previously treated unresectable or metastatic melanoma
Target Patients
Read-out Milesstone(s)
Publication
2022
TBD
110 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation